Patients in the second lowest quintile of testosterone level had a 53% increased death risk compared with those in the highest quintile.
In a small study, the treatment was associated with a 4-fold increase in average ejaculation time.
Study shows it can provide durable oncologic control with a low risk of tumor recurrence.
Researchers observe benefit in prostate cancer patients with 2 or more adverse pathologic features.
Pelvic lymph node dissection in high-risk patients is 2.5 times more likely in those undergoing open rather than robotic-assisted surgery.